Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934134 | 0.81 | ALDH1A1 (0.47) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL979441 | 0.78 | ALDH1A1 (0.45) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL9036705 | 0.76 | PIK3CD (0.32) | — | |
| SCHEMBL9035649 | 0.74 | — | — | |
| SCHEMBL24564744 | 0.73 | KMT2A (0.46) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL1200818 | 0.73 | KMT2A (0.46) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL22104255 | 0.73 | ALDH1A1 (0.38) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL23352576 | 0.73 | ALDH1A1 (0.38) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL20173448 | 0.71 | ALDH1A1 (0.44) | ALDH1A1RAB9ANPC1TSHRHPGD | |
| SCHEMBL14280083 | 0.71 | ALDH1A1 (0.37) | ALDH1A1RAB9ANPC1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051575-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-5942641-A | TREATMENT OF ALZHEIMER'S DISEASE, NERVOUS SYSTEM DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0655992-B1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0791570-A1 | Fluorenone derivatives, process for preparing the same and central or peripheral nerve degeneration repair and protective agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| EP-0655992-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051575-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | HPD, HAAO, CYP8B1 | ALDH1A1 2708/4885RAB9A 3516/4885NPC1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.